UK Prospective Diabetes Study (UKPDS), for example, a 1% increase in Hb A1c was associated with a 28% increase in risk of PAD (95% CI 12, 46), 8 independent of other factors including age, systolic blood pressure, smoking and prior cardiovascular disease. The incidence of PAD increased steadily with the duration of diabetes, and various independent risk factors were identified in UKPDS (Table 1) .
Pre-diabetic states of insulin resistance À obesity, impaired glucose tolerance and hyperinsulinaemia À are also associated with an excess risk of cardiovascular disease. Epidemiological studies have identified insulin resistance and hyperinsulinaemia, independent of glucose levels, as independent risk factors for PAD in both diabetic and non-diabetic subjects. 9, 10 Four principal mechanisms have been proposed to explain how hyperglycaemia affects vascular structure and function: (1) increased oxidative stress and free radical-mediated damage 11 ; (2) formation of advanced glycosylation end-products 12 ; (3) diversion of glucose into the aldose reductase pathway; and (4) activation of one or more isozymes of protein kinase C (PKC), especially PKC-b, 13 which in turn phosphorylates and regulates numerous substrates involved in endothelial function and vascular permeability.
Hyperglycaemia increases oxidative stress through the generation of reactive oxygen species, and by reducing intracellular levels of the natural antioxidants such as vitamins C and E. This in turn accelerates the atherosclerotic process via several mechanisms (e.g. inactivation of endothelium-derived nitric oxide, toxicity to endothelial, cells, and increased oxidation and deposition of low-density lipoprotein (LDL)-cholesterol in the vessel wall. 11 Hyperglycaemia causes non-enzymatic glycosylation of a variety of proteins and lipoproteins in the blood vessel wall to form advanced glycation endproducts (AGEs). 12 AGEs accelerate the structural and functional abnormalities associated with atherosclerosis, in part by binding to receptors for AGE and promoting LDL uptake into macrophages creating characteristic foam cells. The receptors for AGEs are upregulated in diabetes, and coupled to activation of NF-jb and vascular cell adhesion molecule (VCAM-1), in turn increasing monocyteÀendothelial cell adhesion.
Hyperglycaemia-induced de novo synthesis of diacylglycerol (DAG) leads to isozyme-specific activation of PKC, especially PKC-b. 13 PKC-mediated phosphorylation of intracellular receptors, enzymes and transcription factors in turn leads to various structural and functional abnormalities, including changes in endothelial permeability. 13 The clinical importance of this pathway has been highlighted by the results of phase IIÀIII trials with a specific PKCb inhibitor, ruboxistaurin, which ameliorates diabetesinduced vascular dysfunction. 14, 15 Role of free fatty acids and insulin resistance in diabetic macrovascular disease Diabetes is a syndrome of metabolic and haemodynamic abnormalities that are collectively associated with structural and functional changes in blood vessels. Hyperglycaemia is closely related to microangiopathy, whereas large vessel complications, such as PAD, may be more influenced by other pathophysiologic mechanisms. For example, free fatty acid (FFA) levels are increased in diabetes, and FFAs impair endothelial function via several pathways. 16 FFAs affect endothelial function by activation of PKC, generation of oxygen-derived free radicals, fueling triglyceride synthesis and by decreasing the activity of nitric oxide (NO) synthase. 17 The characteristic dyslipidaemia of type 2 diabetes, which is caused, in part, by FFAs promoting triglyceride (TG) synthesis and lowering high-density lipoprotein (HDL)-cholesterol levels, also tends to increase the amount of small, dense atherogenic LDL particles in the circulation.
Type 2 diabetes is also associated with peripheral and hepatic insulin resistance and a compensatory hyperinsulinaemia. Insulin stimulates NO production from endothelial cells via increasing NO synthase activity. 18 In patients with diabetes, insulin-mediated (endothelialdependent) vasodilation is impaired, 19 and correlates inversely with the metabolic defect in insulin signalling. 20 Interestingly, drugs (e.g. metformin or glitazones) or lifestyle interventions (e.g. exercise) that improve insulin sensitivity also improve endothelial function. 21 
Evidence that therapeutic interventions in patients with diabetes improve cardiovascular and=or lower limb outcomes
Bearing in mind that diabetes is a syndrome that includes a cluster of abnormalities, what evidence is there that interventions to lower either glucose, lipid or blood pressure levels in patients with diabetes improves lower limb symptoms and=or lower limb outcomes?
Improving glycaemic control Several large trials have evaluated the effects of tight glycaemic control on the progression of PAD. The Diabetes Control and Complications Trial (DCCT) randomized 1441 patients with type 1 diabetes to either intensive or conventional blood glucose control (mean Hb A1c in the two groups was 7.2% vs 9.1%, respectively). There were 46 major peripheral vascular events during the trial (20 in the intensive group vs 26 in the conventional group), and tight glucose control resulted in a 22% relative risk reduction in major lower limb complications, which was not statistically significant (95% CI À 41, 57). 22 There was a 42% relative risk reduction for the combined endpoint of coronary and peripheral arterial events with intensive glucose control (p < 0.082).
In the UKPDS, the effect of intensive blood glucose control was investigated in 3867 patients with newly diagnosed type 2 diabetes. Average Hb A1c during 10 years of follow-up was 7.0% in the intensive group versus 7.9% in the conventional group. There was a clear trend towards a reduction in deaths from peripheral vascular disease (relative risk 0.26, p ¼ 0.12) and fewer amputations (relative risk 0.61, p ¼ 0.099), but neither endpoint achieved statistical significance. 23 Although treatment of obese patients with metformin had a favourable effect on cardiovascular outcomes overall, there was no evidence of a specific effect of metformin on amputation rates. 24 Lowering blood pressure Hypertension is clearly an important player in diabetesassociated PAD. Each 10 mmHg increase in systolic blood pressure in the UKPDS was associated with a 25% increase in risk ( Figure 1 ). The Edinburgh Artery Study even suggested that patients with diabetes no longer had a significantly higher risk of PAD after adjustment for systolic blood pressure and lipid levels. 25 In the UKPDS analysis of interventions, tight blood pressure control had no significant effect on PAD (relative risk 0.51, 95% CI 0.19, 1.37), but a reduction of 10 mmHg in systolic blood pressure translated into a (non-significant) 16% reduction in risk of lower limb amputation or peripheral vascular disease-related mortality. 26 The Appropriate Blood-Pressure Control in Diabetes (ABCD) study showed that in a small subgroup of patients with type 2 diabetes and established PAD, and a baseline diastolic blood pressure of 80À89 mmHg (n ¼ 53), intensive antihypertensive treatment with either enalapril or nisoldipine reduced the number of major cardiovascular events from 12 to 3 (p ¼ 0.046). Further analysis of this subgroup suggested that intensive blood pressure control (mean blood pressure over 4 years 128=75 mmHg) effectively cancelled out the excess risk of a cardiovascular event associated with PAD. 27 Treating dyslipidaemia Although total cholesterol levels are no higher among patients with diabetes compared with non-diabetic subjects, type 2 diabetes is associated with a more atherogenic lipid profile, in particular a higher fraction of small dense LDL particles and low HDL-cholesterol levels. Reduced levels of HDL-cholesterol were identified as an independent risk factor for PAD in the UKPDS. 8 The Heart Protection Study (HPS) is the largest trial to have examined the effects of statins on cardiovascular outcomes in patients with diabetes. 28 A total of 5963 patients with diabetes were randomized to simvastatin 40 mg daily or placebo, and statin therapy resulted in a significant reduction in peripheral macrovascular complications in the diabetic subgroup (5.2% vs 6.5%, p ¼ 0.03). This endpoint included any peripheral artery surgery, angioplasty, lower limb amputation or ischaemic leg ulcer.
Although only 4% of participants in the Scandinavian Simvastatin Survival (4S) study had intermittent claudication at baseline, the number of cases of new or worsening claudication during the trial was significantly less in the statin treatment group. 29 This adds further support to the notion that statins have disease-modifying effects on atherosclerosis in the lower limb.
Impact of diabetes on symptoms and treatment responses in PAD
The symptoms of PAD include intermittent claudication and, in critical ischaemia, rest pain and=or ischaemic ulceration. The nature and severity of symptoms due to PAD is related not only to the degree of occlusive arterial disease but also the extent to which compensatory mechanisms have been activated (e.g. collateral vessel formation).
Diabetes and collateral vessel formation
It has been recognized for many years that growth of collateral vessels is an important compensatory mechanism in chronic myocardial and lower limb ischaemia. Studies of the coronary circulation in humans have shown a significant reduction in collateral vessel formation in patients with diabetes, and similar results have been obtained in animal models of PAD. 30 The mechanism by which diabetes may inhibit the development of collateral vessels is unclear, but several hypotheses have been proposed. For example, reduced expression of vascular endothelial growth factor (VEGF) and=or reduced VEGF-induced migration of monocytes (a key step in angiogenesis) has been reported in diabetes. 31 Treatments for intermittent claudication À impact of diabetes on therapeutic response Several randomized controlled trials have shown that a structured exercise programme improves symptoms of intermittent claudication. There is some evidence that patients with diabetes also respond to exercise, 32 and subgroup analyses of multicentre drug trials also confirm that patients with diabetes respond to cilostazol 33 and pentoxifylline. 32 Summary and recommendations PAD is very common in patients with diabetes. Furthermore, lower limb vascular disease in diabetes tends to be more diffuse, distal and calcified, and collateral vessel formation is impaired. Not surprisingly, therefore, clinical outcomes (e.g. amputation and revascularization rates) are consistently worse among patients with diabetes and PAD. The risk of acute limb-threatening or acute lifethreatening cardiovascular events is at least twofold higher among diabetics with PAD compared with non-diabetics, and therefore vigorous secondary prevention (if only to reduce cardiac and stroke risk) is mandatory.
Unfortunately, lower limb outcomes have only been included as secondary endpoints in randomized clinical trials of glucose-, blood pressure-and lipid-lowering therapies in patients with diabetes, and the major trials included only very small numbers of patients with PAD at randomization. Thus, none of these studies has had sufficient power to provide firm evidence-based conclusions. Nevertheless, in the UKPDS every 1% increase in Hb A1c was associated with a 28% increased risk of PAD, and a 10 mmHg reduction in systolic blood pressure translated into significantly fewer diabetes-related deaths and 16% fewer lower limb amputations. There is, however, good evidence from the diabetic cohort in the HPS that lipidlowering therapy significantly reduces the number of peripheral vascular complications (a composite of revascularization, ischaemic ulceration and amputation).
Finally, there is some evidence from subgroup analyses of randomized treatment trials that patients with diabetes respond as well as non-diabetics to symptom-relieving interventions such as exercise therapy and cilostazol.
